Background and objective: Usual gait speed over 4 m (4MGS) is an established functional performance measure in older adults that consistently predicts adverse health outcomes, but few data exist in idiopathic pulmonary fibrosis (IPF). We assessed the reliability of 4MGS, its relationship with established outcome measures and its responsiveness to pulmonary rehabilitation. Methods: In four prospective IPF cohorts, 4MGS interobserver (n = 46) and test-retest (n = 46) reliability, concurrent validity (n = 65 and n = 62) and responsiveness (n = 60) were determined. The phenotypic characteristics of all patients stratified according to slow 4MGS (<0.8 m/s) were compared, including lung function parameters, HRCT of the chest, 6-min walking distance (6MWD), Medical Respiratory Council (MRC) dyspnoea score, King's Brief Interstitial Lung Disease (KBILD) questionnaire and Gender, Age and lung Physiology (GAP) prognostic index. Results: Intra-class correlation coefficients for interobserver and test-retest reliability were 0.996 and 0.983, respectively. There was a strong association between 4MGS and 6MWD (r = 0.76; P < 0.0001) and moderate correlations with MRC (r = −0.56), KBILD (r = 0.44) and GAP index (r = −0.41); all P < 0.005. 4MGS improved significantly with pulmonary rehabilitation (mean (95% CI) change: 0.16 (0.12-0.20) m/s), effect size 0.65. Patients with slow 4MGS had significantly worse exercise performance (6MWD: −167 (−220 to −133) m), dyspnoea, health status and prognosis index than those with preserved 4MGS, despite similar lung function and HRCT parameters. Conclusion: 4MGS is a simple, reliable, valid and responsive tool that may detect a patient phenotype
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF), a disease of older people, is a progressive fibrosing lung condition with a median survival of 2.8-4.2 years. 1 It is increasingly recognized that aging and related extra-pulmonary manifestations, such as muscle dysfunction, depression and cardiovascular disease, contribute to morbidity in IPF. assessment tools outside of lung function and thoracic imaging that reflect these aspects. [3] [4] [5] Due to the progressive nature of IPF, these tools should be feasible and reproducible in relevant healthcare environments, from the clinic to the hospital bedside, home and palliative care settings and acceptable to those with severe exertional dyspnoea.
The 6-min walking test (6MWT) is the most widely used measure of functional capacity in IPF 6, 7 but has some limitations. Practical considerations, such as the requirement of an unobstructed, straight, 30-m course limits its utility in some settings. This is particularly relevant for people with advanced disease where the clinical assessment may take place in the home, palliative or critical care environment. 8 Furthermore, the 6MWT may be less acceptable or impossible to perform in people with advanced ventilatory limitation or intolerable dyspnoea with this 'floor effect' potentially contributing to missing data in clinical and research settings. 9 Therefore, there is a need for other tools to supplement the 6MWT in the assessment of functional performance in IPF.
Four-metre gait speed (4MGS), a measure of usual walking speed, is widely used in gerontology as a measure of functional and lower limb performance 10 and a surrogate marker of sarcopenia and frailty. 11 It has been consistently shown to be an independent predictor of physical and cognitive disability, falls, hospitalization and mortality in community-dwelling elders, 10, 12, 13 and is often described as a 'vital sign' or indicator of 'multisystem well-being'. 12, 14 4MGS has been shown to be feasible in home, 15 acute hospital 16 and outpatient settings. 17 In older adults, slow gait speed is defined as <0.8 m/ s, 12, 18 corresponding to a reduction in median life expectancy. 12 The relevance of 4MGS to chronic respiratory disease has not been fully realized, with studies largely confined to chronic obstructive pulmonary disease 16, 17, 19, 20 or acute respiratory distress syndrome. 21 To date no studies have examined 4MGS in an IPFspecific population, but three have evaluated gait speed in interstitial lung disease (ILD) patients. [3] [4] [5] Significant associations between 4MGS and measures of dyspnoea and exercise capacity were reported in people with chronic lung disease (n = 55 ILD) 3 and ILD 5 and 4MGS was shown figuratively to improve post-pulmonary rehabilitation in ILD patients but absolute data was not reported which renders interpretation difficult. 5 Furthermore, in one study, gait speed was measured over 2.4 m 4 a distance which is not sufficiently long to ensure measurement accuracy or satisfactory test-retest reliability. 22, 23 Accordingly, we hypothesized that 4MGS may be a useful assessment tool in IPF and postulate that it may play a particular role as an assessment or stratification tool in advanced IPF when the 6MWT might become less acceptable to patients or less feasible to perform. The aims of the study were to: (i) determine the reliability, concurrent validity and responsiveness of 4MGS in IPF and (ii) describe the phenotypic characteristics of IPF patients and 'slow gait speed' phenotype.
METHODS

Study participants
All participants were prospectively recruited from outpatient respiratory, pulmonary rehabilitation and ambulatory oxygen assessment clinics at the Royal Brompton and Harefield NHS Foundation Trust, UK between January and December 2015. We included people diagnosed with IPF by a specialist ILD multidisciplinary team according to international guidelines, 24 and excluded those with co-morbidities that would make exercise unsafe (e.g. unstable ischemic heart disease). All participants provided informed written consent and the studies were approved by the LondonRiverside Research Ethics Committee (14/LO/2248, 14/LO/2247, 15/LO/0015) and registered on clinicaltrials.gov (NCT02445157, NCT02436278, NCT02530736).
Measurements
4MGS was measured on a flat, 4-m course with a standing start with participants walking at their usual speed as previously described. 17 The assessment was undertaken by trained research staff and physiotherapy assistants who followed a standard operating procedure. Two tests were performed with minimal rest and the faster of the two, measured by stopwatch, was used to calculate gait speed. Further details are available at www.healthmeasures.net and in Appendix S1, Supplementary Information.
Pulmonary function tests included spirometry (forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC)) and diffusion capacity of carbon monoxide (DL CO ) (Jaeger Master Screen PFT, Carefusion Ltd., Basingstoke, UK). 25 The composite physiologic index (CPI) 26 and the Gender, Age and lung Physiology (GAP) index, a prognostic staging system 27 were calculated as previously described. HRCT scans were obtained using a 64-slice multiple detector scanner (Somatom Sensation 64, Siemens, Munich, Germany) and visually scored by two sub-specialist, experienced, thoracic radiologists (D.M.H., J.J.) for the extent of ILD (to the nearest 5%) as described previously. 28 The 6MWT was conducted on a 30-m course according to international technical standards. 8 The incremental shuttle walk (ISW) was conducted on a 10-m course, as previously described. 29 Health status was measured using the King's Brief Interstitial Lung Disease (KBILD) questionnaire. 30 The Medical Research Council (MRC) dyspnoea scale 31 was used to assess dyspnoea and respiratory disability, whilst co-morbidity burden was quantified using the age-adjusted Charlson comorbidity index. 32 Reliability, validity and stratification Study 1 4MGS simultaneously. We recruited participants for this study from outpatient respiratory and pulmonary rehabilitation clinics at Harefield Hospital. The study flow diagram is in Appendix S2 (Supplementary Information).
Study 2
The concurrent validity of 4MGS was assessed using a prospective study comprising two independent cohorts. The main cohort was recruited from a specialist ILD clinic at the Royal Brompton Hospital. Measurements included 4MGS, pulmonary function tests (calculated CPI and GAP index), HRCT, 6MWT, KBILD and MRC. An independent validation cohort was recruited from ambulatory oxygen assessment clinics at Harefield Hospital; patients underwent 4MGS, spirometry, 6MWT and MRC. The flow diagrams for these validation cohort studies are in Appendix S2 (Supplementary Information).
Patients in the main cohort were stratified according to the gait speed prognostic cut-point recommended by expert consensus groups (slow gait speed: <0.8 m/s; preserved gait speed: ≥0.8 m/s) 12, 18 and the 6MWT distance (6MWD) prognostic cut-point (6MWD <250 and ≥250 m 7 ). The between group differences in phenotypic characteristics were compared.
Response to pulmonary rehabilitation Study 3
IPF patients were prospectively recruited from pulmonary rehabilitation clinics at Harefield Hospital and underwent a multidisciplinary, outpatient 8-week pulmonary rehabilitation programme as previously described. 
Statistical analysis
Details of the power calculations for each study are presented in Appendix S3 (Supplementary Information). Data analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, USA) and SPSS version 22 (IBM, New York, USA). Single measure intra-class correlations (ICCs) of consistency and random effect were calculated with 95% CIs to examine inter-observer and test-retest reliability. Measurement variability was determined by calculating the standard error of measurement (SEM) and percentages of SEM (SEM%). Bland-Altman plots were plotted to demonstrate the 95% limits of agreement. Pearson's correlation coefficient (Spearman's rank for non-parametric data) was used to quantify the correlation between 4MGS and other measures. Multivariable regression was used to investigate determinants of 4MGS. 6MWD, MRC, GAP index, BMI, age-adjusted Charlson comorbidity index and KBILD-T were considered as independent variables. Age, sex, FVC% predicted and DL CO % predicted were not considered as they are components of the GAP index. After checking for colinearity between independent variables (r < 0.5), a stepwise approach was used to retain or remove them from the model; entry criterion P < 0.05, removal criterion P ≥ 0.10. Between-group differences were assessed using unpaired t-tests (Mann Whitney U-test for nonparametric data). Paired t-tests (Wilcoxon Signed Rank test for non-parametric data) were used to compare outcomes before and after pulmonary rehabilitation and the effect size was calculated using Cohen's d. Statistical significance was considered at P < 0.05.
RESULTS
Reliability
Study 1
The baseline characteristics of the recruited 46 patients are presented in Table 1 . 4MGS showed high interobserver and test-retest reliability with ICC values (95% CI) of 0.996 (0.992-0.998) and 0.983 (0.970-0.991) respectively. The mean differences between test occasions and observers were 0.001 and 0.01 m/s respectively with no significant change in gait speed between the two occasions (P = 0.85) or between observer values (P = 0.42). Measurement variability was low with SEM and SEM% values of 0.002 and 0.16% for inter-observer and 0.0002 and 0.65% for test-retest reliability respectively. Narrow limits of agreement between observers (0.05 to −0.04) and occasions (0.09 to −0.09) were demonstrated in the Bland-Altman plots. 
Validity and stratification Study 2
The baseline characteristics of the 65 recruited patients and the relationship between 4MGS and other outcome measures are reported in Table 2 . Seven patients used a walking aid whilst seven other patients were prescribed ambulatory oxygen. 4MGS was strongly correlated with 6MWD (r = 0.76, P < 0.001), and had a moderately strong relationship with health status, (KBILD total: r = 0.44, P ≤ 0.001 and a negative correlation with MRC (r = −0.56, P < 0.0001) and GAP index (r = −0.41; P = 0.002). No significant relationships were seen between 4MGS and HRCT extent of disease, nor with lung function parameters such as FVC or DL CO % predicted.
The baseline characteristics of the independent validation cohort (n = 62) undergoing ambulatory oxygen assessment are presented in Table 3 . Similar to the main cohort, 4MGS correlated strongly with 6MWD (r = 0.85, P < 0.0001), and negatively with MRC (r = −0.59, P < 0.001).
Using a stepwise multivariable linear regression model to describe 4MGS, 6MWT alone explained 57% of the variance in 4MGS (Table 4 , Model 1). However, the addition of GAP index explained 67% of the variance in 4MGS (Table 4, Model 3) . The equation to predict 4MGS was: mean (95% CI) 4MGS = 0.001 (0.001-0.002) × 6MWT − 0.040 (−0.078 to −0.002) × GAP index + 0.586 (0.356-0.817) m/s, r 2 = 0.67, P < 0.001. In the main cohort, 24 (37%) participants had a 'slow 4MGS' and 63% had preserved 4MGS. Those with slow 4MGS were older, but there were no differences in sex distribution, lung function parameters, radiological quantification of ILD or use of oxygen therapy or antifibrotic medication. However large deficits in exercise capacity, respiratory disability, health status, multidimensional prognostic index and use of a walking aid were observed in the slow 4MGS group (Table 5 and Fig. 1) . In contrast, when stratified according to the 6MWD prognostic cut-point, significant between group differences were only observed in MRC, 4MGS as well as use of a walking aid and long-term oxygen therapy (Table 5 ).
Response to pulmonary rehabilitation Study 3
The baseline characteristics of the 60 patients who completed pulmonary rehabilitation are recorded in Table 6 . 4MGS was strongly correlated with ISW 
DISCUSSION
This study determines the reliability, validity and responsiveness of 4MGS in an IPF-specific population. We demonstrated high inter-observer and test-retest reliability and in two independent cohorts, 4MGS correlated strongly with 6MWT distance and moderately with measures of dyspnoea, health status and a multidimensional prognostic index. When used to stratify participants according to slow gait speed, 4MGS could identify differences in clinically relevant characteristics such as exercise capacity, health status, dyspnoea, prognosis index and use of a walking aid despite similar lung function and radiological parameters. In contrast, only differences in dyspnoea, gait speed were observed when participants were stratified according to the 6MWT prognostic cut-point. We propose 4MGS provides in Appendix S1 (Supplementary Information) to the 6MWT and has potential as a simple tool in the assessment and stratification of patients with IPF.
There is a paucity of data on 4MGS in this population. In earlier work, DePew et al. studied 70 people with chronic lung disease (n = 55 ILD-IPF data not reported) and demonstrated, like our study, a strong correlation between 4MGS and 6MWT (r = 0.70) and a significant negative correlation with MRC (r = −0.44) in the whole group. 3 Mendes et al. measured the short physical performance battery (SPPB) (a component of which is usual gait speed measured over 2.4 m) in 26 advanced ILD patients (n = 23 IPF) listed for lung transplantation and demonstrated lower SPPB scores compared with 12 age-matched controls. 4 Absolute gait speed values were not reported and the relationship between gait speed and measures of functional status were not presented. Furthermore, 2.4 m may not be sufficiently long to ensure measurement accuracy 22 and has worse test-retest reliability compared to using 4 m. 23 In a study involving 52 ILD patients (n = 20 IPF), Ryerson et al. reported a weak but significant relationship between gait speed and measures of dyspnoea (Baseline Dyspnoea Index: r = −0.36; University of California San Diego Shortness of Breath Questionnaire: r = 0.37). 5 They also showed figuratively that 4MGS improved with a 6-9-week outpatient pulmonary rehabilitation programme in 54 ILD patients (n = 22 IPF) (P = 0.01), but neither absolute values nor effect size 
229 (103) were reported leading to difficulty with data interpretation. 5 To our knowledge, our study is the first to report the reliability of 4MGS, provide evidence to support its validity as a measure of functional status and stratification tool, and demonstrate its responsiveness to pulmonary rehabilitation in adequately powered IPFspecific cohorts.
There are some limitations to 4MGS and our study. First, there is a recognized 'ceiling effect' associated with 4MGS, 19 and therefore it may have more value as an assessment or stratification tool in people with more advanced IPF or limited functional capacity than in those with well-preserved functional status. Second, 4MGS is not a measure of peak exercise capacity, 34 but an indicator of functional impairment, particularly in frail older patients, and has been previously used as a functional outcome measure in interventional pharmacological trials 35 as well as a surrogate marker of sarcopenia and frailty. 11 Third, as the study participants were primarily outpatients attending specialist ILD clinics at tertiary centres, our data need to be corroborated in other IPF populations and settings. Fourth, we were unable to comment on the longitudinal validity of 4MGS in IPF, particularly with regards to prognostic value. However, we were able to demonstrate that the 4MGS was responsive to pulmonary rehabilitation, and as responsive as the ISW, an established field walking test widely used by the pulmonary rehabilitation community. 19 Future research is needed to estimate what constitutes a clinically important change in 4MGS, and whether longitudinal change in 4MGS reflects disease progression.
4MGS has several attractive properties. It is cheap and quick to perform, and requires little space. As walking is familiar to the vast majority of adults, the test is easy to understand and has been shown to be reliable even in people with cognitive dysfunction. 36 These properties mean that 4MGS could be adopted in almost any clinical environment including the home 22 or hospital bedside. 16 We speculate that 4MGS may play a particular role in measuring functional performance in advanced IPF when field walking tests, such as the 6MWT, become less acceptable to or impossible for patients with severe ventilatory limitation or dyspnoea. 37 Furthermore, the 6MWT, which requires a 30 m course, 8 is not feasible in some healthcare settings, such as the home, nursing home, hospice, acute care or many clinic settings, and the need to repeat the test due to learning effect makes it more timeconsuming than simpler functional capacity tests such as the 4MGS. Our data also suggest that the 4MGS is not just a shorter, simpler, less time-consuming 6MWT. Although the two measures correlated strongly, 6MWT only explained 57% of the variance in the 4MGS. Despite the simplicity of the 4MGS, we showed that stratifying according to 'slow gait speed' identified patients with significantly reduced exercise capacity, increased dyspnoea and poor health status in comparison to those with preserved gait speed. However, there was no significant difference in lung function or HRCT results between slow and preserved gait speed groups, suggesting that extra-pulmonary factors such as aging, skeletal muscle dysfunction and frailty 38, 39 contribute significantly to walking speed. We propose that the incorporation of 4MGS into the routine assessment of patients with IPF would be feasible to implement in many healthcare settings, and would supplement information provided by traditional lung function tests and thoracic imaging.
In conclusion, 4MGS as a simple functional performance measure and stratification tool used in gerontology is reliable, valid and responsive in IPF. Compared to those with preserved gait speed, the 'slow gait speed' phenotype is characterized by significantly reduced exercise capacity, increased dyspnoea and impaired health status despite comparable lung function and HRCT abnormalities.
